Last reviewed · How we verify
Pneumococcal polysaccharide-protein conjugate vaccine
Pneumococcal polysaccharide-protein conjugate vaccine is a Biologic drug developed by CIPRA SA. It is currently in Phase 1 development. Also known as: PncCV.
At a glance
| Generic name | Pneumococcal polysaccharide-protein conjugate vaccine |
|---|---|
| Also known as | PncCV |
| Sponsor | CIPRA SA |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
- Irritability
- Drowsiness
- Pain
- Redness
- Loss of appetite
- Swelling
- Fever
- Increase in limb circumference
- Somnolence
- Pyrexia
- Upper respiratory tract infection
- Crying
Key clinical trials
- Influence of Methotrexate Discontinuation on Immunogenicity After PCV-20 Vaccine in Patients ARDs (PHASE4)
- Vaccine Responses in Patients With B Cell Malignancies (PHASE4)
- PCV24 Clinical Trial in Infants and Young Children Aged 2 Months (Minimum 6 Weeks) to 71 Months (PHASE2)
- Opportunistic Pneumococcal Immunisation Trial in MALnutrition (PHASE4)
- Study of DTwP-HepB-Hib-IPV (SHAN6™) Vaccine Administered Concomitantly With Routine Pediatric Vaccines to Healthy Infants and Toddlers in Thailand (PHASE3)
- Infant Malaria Vaccine Schedule Optimization (PHASE2)
- Safety, Tolerability, and Immunogenicity of V110 or V114 Co-administered With a Booster Dose of mRNA-1273 in Healthy Adults (V110-911) (PHASE3)
- Phase Ⅱ Clinical Trial of 24-valent Pneumococcal Polysaccharide Conjugate Vaccine (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Pneumococcal polysaccharide-protein conjugate vaccine CI brief — competitive landscape report
- Pneumococcal polysaccharide-protein conjugate vaccine updates RSS · CI watch RSS
- CIPRA SA portfolio CI
Frequently asked questions about Pneumococcal polysaccharide-protein conjugate vaccine
What is Pneumococcal polysaccharide-protein conjugate vaccine?
Pneumococcal polysaccharide-protein conjugate vaccine is a Biologic drug developed by CIPRA SA.
Who makes Pneumococcal polysaccharide-protein conjugate vaccine?
Pneumococcal polysaccharide-protein conjugate vaccine is developed by CIPRA SA (see full CIPRA SA pipeline at /company/cipra-sa).
Is Pneumococcal polysaccharide-protein conjugate vaccine also known as anything else?
Pneumococcal polysaccharide-protein conjugate vaccine is also known as PncCV.
What development phase is Pneumococcal polysaccharide-protein conjugate vaccine in?
Pneumococcal polysaccharide-protein conjugate vaccine is in Phase 1.
What are the side effects of Pneumococcal polysaccharide-protein conjugate vaccine?
Common side effects of Pneumococcal polysaccharide-protein conjugate vaccine include Irritability, Drowsiness, Pain, Redness, Loss of appetite, Swelling.
Related
- Manufacturer: CIPRA SA — full pipeline
- Also known as: PncCV
- Compare: Pneumococcal polysaccharide-protein conjugate vaccine vs similar drugs
- Pricing: Pneumococcal polysaccharide-protein conjugate vaccine cost, discount & access